It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Polycomb group family is a class of proteins that have important roles in both physiological and pathological processes, and its family member Chromobox homolog 8 (CBX8) regulates cell differentiation, aging, and cell cycle progression in numerous carcinomas; however, the effects and underlying mechanisms of CBX8 in hepatocellular carcinoma (HCC) are rarely reported. We found that CBX8 expression in clinical HCC specimens correlates inversely with patient survival. In HCC cells, we found that enforced overexpression of CBX8 induces epithelial–mesenchymal transition, invasive migration, and stem cell-like traits, which are associated with increased tumor growth and metastasis in mice. Conversely, CBX8 silencing inhibits the aggressive phenotype of HCC cells that have high CBX8 expression. Mechanistically, CBX8 modulates H3K27me3 in the gene promoter of bone morphogenetic protein 4 (BMP4), which is associated with active BMP4 transcription and, consequently, the activation of Smads and mitogen-activated protein kinases. BMP4 expression reverses the effects of CBX8 silencing in inhibiting epithelial–mesenchymal transition, stemness, and metastasis. Our results establish CBX8 as a critical driver of HCC stem cell-like and metastatic behaviors and characterize its role in modulating BMP4 expression. These findings have implications for the targeting of CBX8 as an approach to HCC prognosis and treatment.
Highlights
1. CBX8 expression in clinical HCC specimens correlates inversely with patient survival.
2. CBX8 promotes HCC proliferation, mobility and invasion (epithelial–mesenchymal transition, EMT), and stemness.
3. CBX8 modulates H3K27me3 in the gene promoter of BMP4, which is associated with active BMP4 transcription, and consequently activated Smads and MAP kinases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f)
2 Chinese Academy of Sciences, CAS Key Laboratory of Separation Sciences for Analytical Chemistry, Dalian Institute of Chemical Physics, Dalian, China (GRID:grid.9227.e) (ISNI:0000000119573309); The Second Hospital of Dalian Medical University, Department of Vascular Surgery, Dalian, China (GRID:grid.452828.1)
3 Medical University of South Carolina, Department of Microbiology and Immunology, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
4 Guangxi Medical University, School of Public Health, Nanning, China (GRID:grid.256607.0) (ISNI:0000 0004 1798 2653)